Alberto Bessudo

Bendamustine in Patients With Rituximab-Refractory Indolent and Transformed Non-Hodgkin's Lymphoma: Results From a Phase II Multicenter, Single-Agent Study

Jonathan W. Friedberg, Philip Cohen, Ling Chen et al. · Journal of Clinical Oncology · 2008 · 298 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Denosumab for Treatment of Hypercalcemia of Malignancy

Mimi I. Hu, Ilya Glezerman, Sophie Leboulleux et al. · The Journal of Clinical Endocrinology & Metabolism · 2014 · 200 citations · Full text

Medicine, Oncology, Pharmacology +16

CHAMPION-1: a phase 1/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma

James R. Berenson, Alan Cartmell, Alberto Bessudo et al. · Blood · 2016 · 94 citations · Full text

Medicine, Hematology, Pharmacotherapy +11

Phase II Trial of Idiotype Vaccination in Previously Treated Patients With Indolent Non-Hodgkin’s Lymphoma Resulting in Durable Clinical Responses

Charles H. Redfern, Troy H. Guthrie, Alberto Bessudo et al. · Journal of Clinical Oncology · 2006 · 89 citations

Medicine, Hematology, Immunology +16

Efficacy and safety of melphalan, arsenic trioxide and ascorbic acid combination therapy in patients with relapsed or refractory multiple myeloma: a prospective, multicentre, phase II, single‐arm study

James R. Berenson, Ralph V. Boccia, David S. Siegel et al. · British Journal of Haematology · 2006 · 83 citations

Medicine, Hematology, Pharmacology +13